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Abstract
Background: Cardiac sarcoidosis (CS) is a potentially fatal condition lacking a single test with acceptable diagnostic
accuracy. 18F-FDG PET/CT has emerged as a promising imaging modality, but is challenged by physiological myocardial
glucose uptake. An alternative tracer, 68Ga-DOTANOC, binds to somatostatin receptors on inflammatory cells in sarcoid
granulomas. We therefore aimed to conduct a proof-of-concept study using 68Ga-DOTANOC to diagnose CS. In
addition, we compared diagnostic accuracy and inter-observer variability of 68Ga-DOTANOC vs. 18F-FDG PET/CT.
Methods: Nineteen patients (seven female) with suspected CS were prospectively recruited and dual tracer scanned
within 7 days. PET images were reviewed by four expert readers for signs of CS and compared to the reference standard
(Japanese ministry of Health and Welfare CS criteria).
Results: CS was diagnosed in 3/19 patients. By consensus, 11/19 18F-FDG scans and 0/19 68Ga-DOTANOC scans were
rated as inconclusive. The sensitivity of 18F-FDG PET for diagnosing CS was 33 %, specificity was 88 %, PPV was 33 %,
NPV was 88 %, and diagnostic accuracy was 79 %. For 68Ga-DOTANOC, accuracy was 100 %. Inter-observer agreement
was poor for 18F-FDG PET (Fleiss’ combined kappa 0.27, NS) and significantly better for 68Ga-DOTANOC (Fleiss’
combined kappa 0.46, p = 0.001).
Conclusions: Despite prolonged pre-scan fasting, a large proportion of 18F-FDG PET/CT images were rated as
inconclusive, resulting in low agreement among reviewers and correspondingly poor diagnostic accuracy. By
contrast, 68Ga-DOTANOC PET/CT had excellent diagnostic accuracy with the caveat that inter-observer variability
was still significant. Nevertheless, 68Ga-DOTANOC PET/CT looks very promising as an alternative CS PET tracer.
Trial registration: Current Controlled Trials NCT01729169.
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Background
Sarcoidosis is an inflammatory disease characterized by
non-necrotizing sarcoid granulomas that are often lo-
cated in the mediastinal lymph nodes and the lungs but
may also affect other organs [1]. In up to 25 % of pa-
tients, the heart may be involved [2]. Whereas pulmon-
ary sarcoidosis is often self-limiting and spontaneously
resolves, cardiac sarcoidosis (CS) causes myocardial in-
flammation and fibrosis that may ultimately lead to ser-
ious heart failure, arrhythmias, and sudden death [3, 4].
Patients with CS should therefore receive high-dose cor-
ticosteroid therapy, which has been demonstrated to im-
prove survival [5, 6].
However, cardiac sarcoid lesions are often patchy and
located in areas not readily accessible by endomyocardial
biopsy. Consequently, histological verification is rare,
and sensitivity of the endomyocardial biopsy is also poor
(<20 %) [7]. In the absence of a proper diagnostic refer-
ence standard, a set of diagnostic criteria laid out by the
Japanese Ministry of Health and Welfare (JMHW) has
gained widespread acceptance. The JMHW criteria are
comprised of various electrocardiographic and imaging
abnormalities including cardiac MRI [8] but also accu-
mulation of 67Ga citrate in the cardiac region imaged by
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conventional planar scintigraphic imaging. The 67Ga cit-
rate planar scan has since the introduction of the JMHW
criteria been surpassed by the superior positron emission
tomography (PET) technique, which is likely to replace
67Ga citrate scintigraphy as a major criterion for CS. PET
scanners have better spatial resolution than conventional
gamma cameras and the widely used glucose analogue
radiotracer 18-fluoro-2-deoxyglucose (18F-FDG) is avidly
taken up by the activated macrophages, epithelioid cells,
and Langerhans giant cells found in sarcoid granulomas.
Thus, 18F-FDG PET/CT have been reported to display
high sensitivity and specificity for detecting CS [9]. Even
though 18F-FDG PET/CT has not been formally incorpo-
rated into the JMHW criteria for CS, other diagnostic al-
gorithms like those put forward by the Heart Rhythm
Society (HRS) [10] include focally increased 18F-FDG in
areas of the myocardium as a sign of CS.
A major obstacle to successful use of cardiac 18F-
FDG in diagnosing CS is related to the non-specific
nature of the radiotracer. Since 18F-FDG is a glucose
analogue, it is taken up by all glucose-consuming tis-
sue including the heart, which relies on a mixture of
glucose (~30 %) and fatty acids (~70 %) for fuel con-
sumption [11]. Pathological 18F-FDG uptake by activated
inflammatory cells infiltrating the myocardium may there-
fore be obscured by physiological 18F-FDG uptake by nor-
mally functioning cardiomyocytes. In addition, even though
myocardial 18F-FDG uptake may be suppressed by various
pre-scan fasting protocols [12, 13], uptake patterns are
often heterogeneous and may mimic pathological uptake
[14]. Visual 18F-FDG PET/CT image interpretation in pa-
tients undergoing diagnostic work-up for suspected cardiac
sarcoidosis is therefore very much reliant on the experience
of the reading nuclear medicine physician.
A better alternative to the non-specific 18F-FDG PET
tracer could be somatostatin receptor (SSTR)-targeted ra-
diotracers like 68Ga-DOTA-NaI-octreotide (DOTANOC)
or 68Ga-DOTA-D-Phe-Tyr-octreotide (DOTATOC). Acti-
vated inflammatory cells (epithelioid cells, multinucleated
giant cells, and some macrophages that are typically found
in sarcoid granulomas) have abundant SSTRs on their sur-
face [15], in particular SSTR2A, whereas normal cardio-
myocytes do not. 68Ga-DOTANOC has a high affinity
for both SSTR2 and 5 and are not taken up by the
normal myocardium to any significant extent [16],
whereas some physiological uptake in the myocardium
is observed using 68Ga-DOTATOC [17]. Signal-to-
noise ratio should thus be advantageous using 68Ga-
DOTANOC allowing for more straightforward and re-
producible image interpretation, even in the hands of
less experienced readers/physicians. A recent case
study demonstrating avid 68Ga-DOTATOC uptake in
the interventricular septum of a patient with convin-
cing signs of CS underscores this notion [18].
Hence, the primary aim of the current study was to
compare the diagnostic accuracy of 18F-FDG PET/CT
and 68Ga-DOTANOC PET/CT for the diagnosis of CS.
A secondary aim was to compare the reproducibility of
image interpretations by comparing inter-observer vari-
ability for the two radiotracers. We hypothesized that
68Ga-DOTANOC PET/CT would outperform 18F-FDG
PET/CT on both aims.
Research design and methods
Subjects
Nineteen patients with suspected cardiac sarcoidosis
were prospectively enrolled from the Department of
Respiratory Diseases or the Department of Cardiology at
Aarhus University Hospital. Volunteers had either biopsy
proven or clinically suspected sarcoidosis and all exhibited
signs of cardiac involvement (arrhythmias or chronic heart
failure). Retrospective reviews of patient files revealed that
the clinical suspicion of sarcoidosis was later withdrawn in
three patients (patients no. 9, 12, and 13—see Table 1).
Ethics, consent, and permissions
All volunteers received oral and written information
concerning the study prior to giving written, informed
consent. The protocol was approved by the Local Ethical
Scientific Committee (1-10-72-200-12), registered at
ClinicalTrials.gov (NCT01729169), and performed in ac-
cordance with the Helsinki Declaration II.
PET acquisition
Patients were scanned with two PET radiotracers within
7 days: 18F-FDG and 68Ga-DOTANOC. All PET/CT stud-
ies were performed using the same Siemens Biograph 64
scanner (Siemens, Germany). Before each PET study day,
patients were instructed to refrain from eating starch-
containing foods and were instructed to fast from 8 pm
the day before the PET scan. Average fasting time was
15 h. PET data acquisition started 60 (18F-FDG) and 90
(68Ga-DOTANOC) minutes after injection of 4 MBq/kg
18F-FDG and 3 MBq/kg 68Ga-DOTANOC, respectively.
Acquisition time was 3 min/bed position. Non-gated CT
imaging was used for attenuation correction. 18F-FDG
PET scans were only performed if blood glucose was
below 7 mmol/liter (126 mg/dl).
Reference standard
In the absence of a validated histopathological reference
standard, we opted for a combination of the revised CS
criteria from 2006 laid out by the Japanese Ministry of
Health and Welfare combined with clinical follow-up.
During the clinical follow-up, electronic medical records
were reviewed and any new arrhythmia, worsening of
cardiac function, or morphological change assessed by
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Table 1 Patient characteristics and clinical presentation
Methotrexate Age Sex Immunosuppressive
therapy












SR ND No Pulmonary/
med. LN
No None None





No None Non-sustained VT, MRI with
anterior late enhancement




Yes Decreased LVEF Left ventricular hypokinesia,
VT, perfusion defects on
scintigraphy





Yes Decreased LVEF Inferoseptal aneurism,
perfusion defect on 82Rb
PET, VT

















enhancement in the septum
+ thickening of the right
ventricle
6 59 M None SR, inferior
Q-wave





No None PVC, RBBB
7 65 M None SR, RBBB, PVC Normal No (claustrophobia) Pulmonary/
med. LN
No None PVC, RBBB
8 36 F None SR, PVC Normal No Pulmonary/
splenic biopsy
No None PVC
















Decreased LVEF Left ventricular hypokinesia,
MRI with late enhancement







11 64 M Prednisolone
5 mg/daily




No Decreased LVEF PVC
12 51 F None Pacemaker
rhythm






13 33 M None SR, ST-depressions
in V5-V6























Table 1 Patient characteristics and clinical presentation (Continued)
14 58 M Methotrexate
10 mg/weekly
SR Normal Yes, normal Pulmonary/
med. LN
No








16 46 F Methotrexate
5 mg/weekly
SR Normal No Pulmonary/
med. LN
No




18 64 M None SR, LBBB Discrete hypokinesia No (nephropathy) Pulmonary/
skin
No Decreased LVEF Discrete hypokinesia of
the septum




Abbreviations: DE-MR delayed enhancement magnetic resonance, ECG electrocardiogram, ECHO echocardiography, EF ejection fraction, FEV1 forced expiratory volume, HR-CT high-resolution computed tomography,
JMHW Japanese Ministry of Health and Welfare, LV left ventricle, LBBB left bundle branch block, med. LN mediastinal lymph node, PVC premature ventricular contractions, RBBB right bundle branch block, SR sinus














echocardiography was considered indicative of cardiac
sarcoidosis irrespective of the status at initial PET scan.
Expert reviews and final PET diagnosis
Cardiac 18F-FDG PET images are difficult to review for
signs of cardiac sarcoidosis. We therefore had four ex-
pert nuclear medicine physicians (P.B., A.H., S.K., and
A.D.) review all studies enabling us to report both diag-
nostic accuracy of the two radiotracers and inter-
observer variability. Readers were blinded to clinical
data, biochemical tests, and results from other imaging
modalities (US and MRI) and performed the image re-
views in a random order. Majority decisions were used
to decide patterns of 18F-FDG uptake and final PET
diagnosis. For both radiotracers, PET scan results were
classified as positive, negative, or inconclusive. For calcu-
lation of diagnostic accuracy, cases in which the majority
decision was inconclusive were considered negative.
18F-FDG PET/CT image analysis
Reviewers were first asked to visually classify 18F-FDG
images into four patterns: “none,” “diffuse,” “focal,” or
“focal on diffuse,” where the none and diffuse patterns
were considered physiological. Next, in case of focal and
focal on diffuse patterns, reviewers were asked to con-
sider whether these were thought to represent a normal
physiological pattern (which is often seen in incomplete
suppression of physiological cardiac 18F-FDG uptake) or
if the uptake was indicative of CS. In this qualitative
assessment, readers were asked to classify the images as
“CS,” “no CS,” or “inconclusive”. Thus, the final 18F-
FDG PET/CT diagnosis was purely qualitative.
For semiquantitative measurements, ROIs (circular
with a radius of 1 cm) were placed in suspected CS
lesions and SUVmax values and anatomic localization
was recorded to compare anatomical precision of the
image review.
68Ga-DOTANOC PET/CT image analysis
68Ga-DOTANOC is not accumulated in the cardiac re-
gion in healthy subjects and consequently, any uptake in
the myocardium above blood pool activity was consid-
ered pathological. All identified areas of focally increased
68Ga-DOTANOC activity were recorded, and SUVmax
values in individual lesions were measured.
Statistics
Patient demographics and baseline characteristics are
summarized as mean ± SD for continuous variables and
frequencies for dichotomous or ordinal variables. Inter-
observer agreement on the diagnosis of CS and patterns
of 18F-FDG uptake was evaluated by estimating the over-
all agreement and the kappa statistic for multiple raters
(experts) per subject (patient), a method put forward by
Fleiss in 1971 [19]. Overall agreement on final diagnosis
using Fleiss’ kappa is an estimate of the probability with
which two randomly selected experts will agree on the
diagnosis in a randomly selected patient. A kappa value
of 0 indicates agreement equivalent to that expected by
chance, negative values indicates agreement even lower
than that. Values between 0 and 0.4 represent poor
agreement, and values between 0.4 and 0.75 represent
fair agreement and values above 0.75 represents excel-
lent agreement.
Sensitivity, specificity, positive predictive value, negative
predictive value, and diagnostic accuracy were calculated
for both radiotracers based on the majority decision as
outlined above.
Results
Characteristics of study subjects
Overall, 19 patients (male to female ratio 12:7, age
(median, range) 54 years (33–67)) with suspected CS
were prospectively enrolled from September 2012 to
December 2014. Patient characteristics are detailed in
Table 1. Median follow-up time was 17 months (range
4–31). One patient died from dilated cardiomyopathy
10 months after the PET scans. The remaining 18 were
either completely discharged from any regular con-
tacts with the outpatient clinic or in stable conditions
at the time of the image reviews.
Patients with cardiac sarcoidosis (reference standard)
In all, three patients fulfilled the JMHW criteria for CS
(see Table 1). By comparison with the entire group of
patients, they were younger (age 37–46) and women
were over-represented (male to female ratio 1:2). All
three patients were treated with high-dose corticoste-
roids for 6 months after which corticosteroid dose was
reduced according to clinical presentation. All three pa-
tients had pacemakers implanted after the diagnosis of
CS was established.
Cardiac 18F-FDG PET—agreement on uptake patterns
The four expert reviewers were asked to categorize
cardiac 18F-FDG uptake according to the patterns sug-
gested by Ishimaru et al. [20]. Somewhat to our surprise,
complete suppression of cardiac 18F-FDG uptake (none
pattern) was accomplished in only 2/19 patients (see
Additional file 1: Table S1). In 11/19 patients, the major-
ity decision on 18F-FDG pattern was diffuse indicating at
least some presumably insulin-independent 18F-FDG
uptake. In 2/3 patients with CS as determined by the ref-
erence standard, 18F-FDG uptake was focal on diffuse,
whereas it was classified as diffuse in the last patient, who
had severely dilated cardiac cavities (see Fig. 3). 18F-FDG
uptake was classified as focal on diffuse or focal in four pa-
tients who did not meet the JMHW criteria (patients no. 7,
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9, 14, and 15) (see Figs. 1 and 2 for example). One of these
patients died of non-cardiac-related disease 10 months after
the PET scans (and never had the sarcoidosis diagnosis con-
firmed), and the three remaining were all discharged with-
out high-dose corticosteroid therapy (since CS was ruled
out by JMHW criteria). At follow-up, these three patients
were all doing well and had no signs of active sarcoidosis.
Overall agreement between the reviewers on patterns of
18F-FDG uptake was 0.72 (Fleiss’ kappa) indicating fair
agreement on the patterns of FDG-uptake.
Cardiac 18F-FDG PET—agreement on diagnosis
Based on the visual inspection of cardiac 18F-FDG up-
take, the expert reviewers were asked to assess whether
the 18F-FDG PET scan indicated CS, no CS, or was in-
conclusive. In 11/19 patients, the majority found the
18F-FDG scan inconclusive; in 5/19 patients, the diag-
nosis was “no sign of sarcoidosis”; and in 3/19 patients,
the majority decision was “cardiac sarcoidosis” (see
Additional file 2: Table S2). Of the three patients with
CS using the JMHW criteria as the standard of truth,
only one patient was classified as such by majority deci-
sion on the 18F-FDG PET. The remaining two patients
with CS had inconclusive scans. False positive scans were
seen in patient 14, where 18F-FDG uptake was seen in the
basal lateral wall (see Fig. 1), and in patient no. 15 (see
Fig. 2), where 18F-FDG uptake near the aortic ostium was
observed. This is often seen in sclerotic valvulopathy.
Overall agreement on the diagnosis of CS by 18F-FDG PET
was 0.27 (Fleiss’ kappa) indicating poor agreement.
Cardiac 18F-FDG PET—diagnostic accuracy
For calculation of diagnostic accuracy, inconclusive scans
were considered negative. Sensitivity of 18F-FDG cardiac
PET for diagnosing CS was 33 % (1/3), specificity was
88 % (14/16), PPV was 33 % (1/3), NPV was 88 % (14/16),
and diagnostic accuracy was 79 %. The binary classifica-
tion data for 18F-FDG is summarized in Table 2.
Cardiac 68Ga-DOTANOC PET—agreement on diagnosis
As anticipated, agreement among reviewers was better
for the 68Ga-DOTANOC scans owing primarily to sig-
nificantly fewer scans categorized as inconclusive. Thus,
no scans were inconclusive by majority decision and
more scans were categorized similarly by all reviewers
(see Additional file 3: Table S3). 3/19 patients were clas-
sified as CS by majority decision (see Figs. 3, 4, and 5).
However, overall agreement assessed by Fleiss’ kappa
was only fair (0.46) which is probably attributable to the
rather modest SUVmax values recorded in the lesions
(ranging between 2.5 and 2.8).
Cardiac 68Ga-DOTANOC PET—diagnostic accuracy
Using the JMHW criteria for CS, 68Ga-DOTANOC cor-
rectly classified all patients and thus had a diagnostic
accuracy of 100 %. The binary classification data for
68Ga-DOTANOC is summarized in Table 3.
Fig. 1 Typical 18F-FDG PET/CT false positive for cardiac sarcoidosis. Left panel: maximum intensity projections (MIPs) of patient no. 14. scanned
after injection of ~370 MBq 18F-FDG and ~300 MBq 68Ga-DOTANOC. Red arrows denote 18F-FDG uptake in hilar lymph nodes (sarcoidosis). The hilar
sarcoidosis is clearly visible on both 18F-FDG PET and 68Ga-DOTANOC PET. Right panel: transaxial slices of the cardiac region with 18F-FDG (top) uptake
in the basal lateral wall of the myocardium (SUVmax 7.4). 68Ga-DOTANOC (bottom) images show uniform activity in the entire cardiac region
(myocardium and blood pool) with no areas of focal uptake effectively ruling out CS. Notice the different SUV scales for the two radiotracers
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Effects of corticosteroid therapy on cardiac 18F-FDG and
68Ga-DOTANOC uptake
Follow-up scans using both tracers were available for pa-
tient no. 4 (see Fig. 5) diagnosed with CS. Interestingly,
the focal on diffuse 18F-FDG uptake pattern was com-
pletely unaltered by corticosteroid therapy whereas all
18F-FDG uptake in affected lymph nodes above and
below the diaphragm was normalized. The focal on dif-
fuse cardiac 18F-FDG uptake pattern could thus safely be
considered physiological.
By contrast, pre-therapeutic 68Ga-DOTANOC uptake
was only increased in a small area in the basal lateral
area, where US showed an aneurism. This pathological
68Ga-DOTANOC uptake was completely abolished by
corticosteroid therapy, and no uptake above blood pool
level was evident in the myocardium. As for 18F-FDG,
68Ga-DOTANOC uptake by affected lymph nodes was
completely absent after therapy indicating an excellent
overall response.
Discussion
In this proof-of-concept study, we have shown that
inflammation in the form of sarcoid granulomas takes
up 68Ga-DOTANOC. By consensus decision, the diag-
nostic accuracy of 68Ga-DOTANOC in diagnosing CS
was 100 %—with the caveat, which inter-observer
agreement was only fair owing to the modest tracer
accumulation in sarcoid lesions. Most importantly,
68Ga-DOTANOC PET/CT images were only rarely
classified as inconclusive reflecting the advantageous
signal-to-noise ratio in the cardiac region. By contrast,
even though expert readers could agree on the cardiac
18F-FDG pattern, insufficient suppression (15 h fast-
ing) of physiological cardiac 18F-FDG uptake resulted
in a large proportion of inconclusive 18F-FDG PET/
CT scans. This study therefore also supports recent
studies [21] that underscore the importance of more
rigorous pre-scan regimens involving either high-fat/
low-carbohydrate or Intralipid/heparin infusions.
Cardiac 18F-FDG PET/CT
Despite a growing body of evidence that supports the
use of cardiac 18F-FDG PET/CT to diagnose CS, nu-
merous problems regarding physiological myocardial
18F-FDG uptake still persist. This becomes particularly
evident when cardiac 18F-FDG PET/CT is imple-
mented in an everyday clinical practice. First, patient
Fig. 2 18F-FDG PET/CT false positive for cardiac sarcoidosis. Left panel: MIPs of patient no. 15 scanned after injection of ~370 MBq 18F-FDG and ~300 MBq
68Ga-DOTANOC. There was avid an 18F-FDG uptake in all areas of the bone marrow and the spleen indicating long-term infection. A few lymph nodes are
visible in the upper mediastinum on the 68Ga-DOTANOC scan. Right panel: transaxial and coronal slices of the cardiac region revealed avid 18F-FDG uptake
in the area around the aortic ostium (yellow arrows) which is often seen in aortic valve sclerosis, but can also be mistaken for uptake in a sarcoid lesion
(SUVmax 7.6). Clear calcifications are seen around the posterior valve on the low-dose CT. On the 68Ga-DOTANOC scan (bottom), there is no
activity above background in the myocardium. By contrast, activity is increased in the pericardium (yellow arrows) and some pericardial fluid is
visible indicating pericarditis
Table 2 Binary classification characteristics of 18F-FDG
CS diagnosis (JMHW criteria)
Positive Negative
FDG diagnosis Positive 1 2 3
Negative/inconclusive 2 14 16
3 16 19
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Fig. 3 Patient with CS in which the 18F-FDG PET/CT was inconclusive due to insufficiently suppressed physiological 18F-FDG uptake by the
myocardium. Left panel: MIPs showing patient no. 5 with dilated cardiomyopathy and multiple 18F-FDG and 68Ga-DOTANOC avid lymph nodes
(red arrows) both above and below the diaphragm. In addition, there is massive and diffusely increased activity in the lung parenchyma (black
arrows) representing active pulmonary sarcoidosis. Right panel: transaxial slices of the cardiac region reveal a focal on diffuse pattern of 18F-FDG
uptake (top) raising suspicion of cardiac involvement (SUVmax 21 in the septum). However, the image was rated inconclusive by a majority of
expert reviewers. By contrast, all reviewers rated the 68Ga-DOTANOC uptake (SUVmax 2.8, target-to-background 3.04) in the septum pathological
(bottom). The patient was treated with corticosteroids and recovered
Fig. 4 Patient with CS. 18F-FDG PET/CT images were rated as inconclusive due to insufficiently suppressed physiological 18F-FDG uptake. Left panel: MIPs
showing 18F-FDG PET/CT (upper) and 68Ga-DOTANOC PET/CT (lower) of patient no. 3. 68Ga-DOTANOC accumulation can be seen in the anterior and lateral
wall (red arrow). Right upper panel: transaxial slices of 18F-FDG showing focal on diffuse 18F-FDG uptake considered inconclusive by a majority of readers.
Right lower panel: 68Ga-DOTANOC accumulation (yellow arrow) is seen in the anterolateral and lateral wall (SUVmax 2.35, target-to-background 1.56). In the
coronal view, it is evident that spill-in activity from the liver may obscure inferior lesions
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preparations are not straightforward: In order to
minimize physiological 18F-FDG uptake by the cardio-
myocytes, lipid levels must be raised while insulin
levels should be suppressed. This is typically achieved
by a combination of fasting, diet interventions, and in-
fusions of Intralipid and heparin. However, fasting for
the recommended 18 h [22] requires skipping at least
one major meal which likely reduces overall compli-
ance. In addition, as few as ~10 % of patients may
obtain complete suppression of physiological cardiac
18F-FDG uptake [23, 24] even if the fast is adhered to.
Patient preparations become even more complicated,
when the fast must be combined with a starch-poor
diet to produce optimal results [12, 13] or when hep-
arin and lipid emulsions (Intralipid) are injected just
prior to or during the scan in order to release more
fatty acids into the circulation [25]. These attempts to
force the cardiac region to rapidly switch from glucose
to lipid fuels for oxidation have produced mixed
results with our own combined Intralipid/heparin/
somatostatin infusion failing to significantly suppress
cardiac 18F-FDG uptake in patients with suspected CS
[26]. To sum up, laborious pre-scan diet and infusion
protocols still result in a high probability of insuffi-
ciently suppressed physiological 18F-FDG uptake. Sec-
ond, when physiological cardiac 18F-FDG uptake is not
suppressed, it is frequently heterogenous [14, 27] with
basal lateral uptake exceeding uptake in other regions
[28]. Calcifications of the aortic valves [29], atrial fib-
rillation [30], and coronary artery disease [31] may
also produce focally or heterogeneously increased 18F-
FDG uptake not related to sarcoidosis. This was most
likely the case in patient no. 15, where focal accumula-
tion of 18F-FDG adjacent to sclerotic aortic valves was
taken as evidence of CS, and in patient no. 14 where a
single focus of 18F-FDG was present in the basal lat-
eral wall. These pitfalls to visual interpretation of
cardiac 18F-FDG PET/CT have prompted a series of
semiquantitative approaches ranging from SUVmax
cut-offs [25, 32] to analyses of cardiac 18F-FDG het-
erogeneity [12]. Analytic improvements are likely to
improve diagnostic accuracy but require such strict
standardization of patient preparation, scan protocols,
and image reconstruction that separate studies in each
PET centre are warranted to establish relevant thresh-
old values.
Fig. 5 The effects of corticosteroid treatment on 18F-FDG and 68Ga-DOTANOC uptake in the cardiac region. Left panel: patient no. 4 (with CS according to
the reference standard) was dual-tracer scanned before treatment with corticosteroids and after 6 months of high-dose prednisolone treatment (initially
50 mg tapering off to 37.5 mg). At diagnosis, there were multiple 18F-FDG and 68Ga-DOTANOC avid lymph nodes on both sides of the diaphragm as well
as accumulation of 68Ga-DOTANOC in the cardiac region (red arrow) (SUVmax 2.64, target-to-background 2.54). The patient was rated as positive for CS on
the 68Ga-DOTANOC PET/CT. Right panel: transaxial slices of the same patient where 18F-FDG uptake in the myocardium (upper row) is similar during both
scans (focal on diffuse) whereas the 68Ga-DOTANOC accumulation (lower row) in the basal inferolateral wall (yellow arrow) is completely abolished
after treatment
Table 3 Binary classification characteristics of 68Ga-DOTANOC
CS diagnosis (JMHW criteria)
Positive Negative
DOTANOC diagnosis Positive 3 0 3
Negative 0 16 16
3 16 19
Gormsen et al. EJNMMI Research  (2016) 6:52 Page 9 of 12
Somewhat disappointingly, diagnostic accuracy of 18F-
FDG PET/CT was rather low in this study when com-
pared with previously published data. However, geography
may to some extent explain this. Thus, the reported fre-
quency of cardiac involvement in patients with sarcoidosis
ranges from 58 % in patients of Japanese origins [33] to
16 % in Scandinavian Caucasians with ECG changes [34].
Focal or heterogenous 18F-FDG uptake in patients with
CS caused entirely by physiological glucose uptake and
not by accumulation in inflammatory cells should thus be
categorized as false positive on a lesion basis, but could in
Japanese patients with sarcoidosis be true positive on a
patient basis (since more than half of all Japanese patients
probably have CS at some stage). This misclassification is
much less likely to occur in Europe or North America,
where the prevalence of CS in sarcoidosis patients is mark-
edly lower. The excellent specificity of 18F-FDG PET/CT
reported by Okumura [35] and Ishimaru [20] who con-
ducted studies in Japan appear to support this notion. Also
in line with this, we observed focal on diffuse 18F-FDG
uptake in CS patient no. 4 on the initial scan and could
therefore classify the scan as positive for CS. However, the
pathological 68Ga-DOTANOC accumulation was located
elsewhere and completely disappeared with corticosteroid
therapy, whereas the post-therapeutic 18F-FDG uptake
pattern was unaltered (see Fig. 5). In our opinion, this indi-
cates normal physiology despite heterogenous 18F-FDG up-
take. The patient was therefore false positive on a lesion
basis but true positive on a patient basis.
68Ga-DOTANOC PET/CT
The use of SSTR-targeted radiotracers to assess sarcoid-
osis disease activity is not a novel idea. Giant cells, epi-
thelioid cells, and lymphocytes constitute the bulk of
active inflammatory cells in sarcoid granulomas and ex-
press SSTRs abundantly. Thus, Kwekkeboom et al. [36]
were able to visualize 97 % of known sarcoid lesions in 46
patients using 111In-labeled pentetreotide (octreotide), a
SSTR analogue visualized by gamma camera technique.
These results were largely reproduced in a later but
smaller study, where 83 % of clinically involved sarcoidosis
sites were identified [37]. No uptake was observed in the
cardiac region in either study. This may at least partly be
explained by the poor spatial resolution of octreotide scin-
tigraphies but also by the composition of patient cohorts
that did not include patients with suspected CS.
The introduction of 68Ga-labeled SSTR ligands may
change this. 68Ga is a generator-produced PET isotope that
has been used to label a range of SSTR-targeting ligands
developed to diagnose and monitor [38] neuroendocrine
tumors. 68Ga-DOTANOC PET/CT binds to SSTR2, 3, and
5 and has better spatial resolution than octreotide scintigra-
phies. In addition, PET and CT images may be fused allow-
ing for better anatomical localization of any suspected
lesion. Somewhat surprisingly, we are unaware of any previ-
ous studies using 68Ga-labeled SSTR ligands to diagnose
CS. Only one case study of a patient with suspected CS has
recently been published in which 68Ga-DOTATOC was
avidly taken up by the interventricular septum indicating
cardiac involvement [18]. In addition to this case study, the
same group has published evidence of 68Ga-DOTATOC ac-
cumulation in post-infarction myocarditis as well as in peri-
carditis further strengthening the point that SSTR ligands
bind to inflammatory cells [39].
Using 68Ga-DOTANOC PET/CT, we were able to cor-
rectly identify all three patients who met the revised
JMHW criteria for CS. Furthermore; we were able to
rule out cardiac involvement in the remaining patients.
As expected, we frequently observed avid 68Ga-DOTA-
NOC accumulation in multiple involved lymph nodes
(see figures), which served as a positive control of ac-
tive sarcoidosis for the visual assessment of cardiac in-
volvement. The rather low prevalence of CS observed
in this patient cohort is comparable to that observed
by Ishimaru et al. (5/32) [20] but somewhat lower than
that reported in a large study by Blankstein et al. (34/
118) [40]. In our opinion, this reflects different patient
recruitment strategies since 18 patients from the
Blankstein study had known cardiac sarcoidosis at the
time of their PET scan.
Importantly, we observed no new arrhythmias or
worsening of left ventricular function in patients clas-
sified as negative for 68Ga-DOTANOC accumulation
in the cardiac region (excluding the patient who died
of other causes) and NPV was therefore excellent.
However, 68Ga-DOTANOC SUVmax values observed
in suspected lesions were only modest compared to
18F-FDG SUVmax values (which were as high as 21 in
patient no. 5). Thus, it is of great importance that
there is no physiological 68Ga-DOTANOC accumula-
tion in the myocardium.
Finally, although a diagnostic accuracy of 100 % was
seen for 68Ga-DOTANOC, this was only obtained by
majority decision, and some inter-rater disagreement
was seen for 68Ga-DOTANOC. Although all raters were
experts with years of PET/CT experience, it is likely that
some of this disagreement was caused by the raters be-
ing unaccustomed to evaluating the cardiac region on
68Ga-DOTANOC images, since this is not part of clin-
ical routine. In contrast, all raters were experienced in
evaluating cardiac FDG uptake, which was reflected by
the relatively high agreement on FDG uptake patterns
(Fleiss kappa 0.72). We believe that inter-rater agree-
ment on pathological cardiac DOTANOC uptake prob-
ably can be substantially improved by exposing the
raters to a 68Ga-DOTANOC training dataset of verified
CS cases. This strategy was not available to us, since
only three patients had active CS and expert readers
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therefore could not undergo a regular training session
with demonstration of CS image characteristics (68Ga-
DOTANOC) for fear that individual patients would
subsequently be recognizable.
Limitations
Several limitations apply to the current study. First, the
prevalence of CS was low with only three patients fulfilling
the JMHW criteria for CS. Should the study have been
adequately powered, it would have required a very large
study population (approximately 400) [41], which is im-
possible for practical and ethical reasons in radiotracer
studies. It is therefore not possible to draw firm conclu-
sions as to the superiority of 68Ga-DOTANOC over 18F-
FDG PET/CT in detecting CS. The findings from this
pilot study should therefore serve more as proof-of-
concept than a definite study of diagnostic accuracy.
Second, only active inflammatory cells express SSTRs
and late-stage CS, which is characterized by fibrosis and
scarring, is therefore unlikely to take up 68Ga-DOTANOC.
In addition, 68Ga-DOTANOC is taken up by inflamma-
tory cells irrespective of their causative factor and is there-
fore not suited to distinguish between sarcoidosis and,
e.g., infective myositis or endocarditis. However, this cav-
eat applies equally to 18F-FDG PET.
Third, the absence of concurrent cardiac MRI scans of
all patients in the present study is also a major limita-
tion. Areas of active inflammation as well as fibrotic
scars display slow wash-out of gadolinium and this late
gadolinium enhancement (LGE) has been demonstrated
to accurately predict the presence of cardiac sarcoidosis.
Thus, Smedema et al. detected LGE in all 12 patients
with cardiac sarcoidosis using the JMHW criteria as a
reference standard. However, LGE may also be a non-
specific finding in, e.g., dilated cardiomyopathy, and con-
sequently, the specificity (78 %) and positive predictive
value (55 %) of MRI was somewhat lower in that study
[8]. Others have developed more elaborated MRI proto-
cols involving T2-mapping which may increase the spe-
cificity of MRI for detecting CS [42]. In summary,
cardiac MRI is an excellent first-line imaging modality in
patients with suspected CS provided there are no con-
traindications to its use. Unfortunately, this may often
be the case in patients with CS since advanced AV-
blocks necessitating rapid implantation of a pacemaker
is often a presenting symptom.
Fourth, the diagnostic accuracy of our 18F-FDG PET/
CT scans was disappointingly low, which may relate to
the pre-scan protocol we opted for. We did not attempt
to control participating subjects’ diet with high-fat meals
preceding the scan, nor did we co-infuse Intralipid and
heparin immediately prior to the scan as advocated by
others (reviewed in [21]).
Conclusions
Cardiac sarcoidosis poses a diagnostic challenge with no
single test available to correctly identify patients. We
herein present data indicating that 68Ga-DOTANOC
PET/CT can be used as an adjunct imaging modality in
patients with suspected CS—preferably as an imaging
substitute for the obsolete 67Ga citrate scintigraphy. In a
small cohort of patients with suspected CS, cardiac
68Ga-DOTANOC PET/CT had excellent diagnostic ac-
curacy and had the advantage over 18F-FDG PET/CT
that no pre-scan fasts, diets, or infusions were required.
However, since this was a pilot study involving only few
cases of CS, the findings must be reproduced in a larger
patient cohort. It should also be noted that solitary infer-
ior lesions may be obscured by physiological activity in
the liver and ventricle.
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